Weight Loss in Patients With COVID-19 and Influenza in Comorbidity With NCDs: a Pilot Prospective Clinical Trial

The goal of this study was to evaluate the effects of the fast weight loss on clinic and laboratory inflammation profile, metabolic profile, reactive oxygen species (ROS) and body composition in patients with COVID and Influenza in comorbidity with NCDs.Primary endpoints: Clinic/infectious/inflammation tests for COVID and Influenza; weight loss during 14 days. Secondary endpoints: fasting blood glucose, HbA1c, blood insulin; systolic/diastolic BP; blood lipids; ALT, AST, chest CT-scan.

Inclusion Criteria:written informed consent form;patients with feverpatients refused for pharmacology therapyweight loss treatment for 12-14 days and +4 weeks follow-up (total 6 weeks)Exclusion Criteria:patients with acute respiratory failure and assisted ventilation requirementrespiratory rate ≥ 30 times per minuteoxygen saturation ≤ 93% by finger oximetry at resting status